The role of nitric oxide in the regulation of glomercular haemodynamics in humans

Nephrology Dialysis Transplantation

Volumn 19, Issue 6, 2004, Pages 1392-1397

  Delles, Christian ^a   Klingbeil, Arnfried U ^a   Schneider, Markus P ^a   Handrock, Renate ^b   Schäufele, Tim ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Angiotensin II; Calcium channel blocker; Glomerular haemodynamics; Humans; Nitric oxide; Receptor blocker

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; N(G) METHYLARGININE; NITRIC OXIDE; VALSARTAN;

ADULT; AGED; ARTERIOLE; ARTERY DILATATION; ARTERY TONE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM;

ADULT; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY GLOMERULUS; MIDDLE AGED; NITRIC OXIDE; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VASODILATOR AGENTS;

EID: 2942746438     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh187     Document Type: Article

References (21)

1. Edwards RM, Trizna W. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J Am Soc Nephrol 1993; 4: 1127-1132
2. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 1995; 268: F885-F898
3. Raij J, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20-32
4. Veelken R, Hilgers KF, Hartner A, Haas A, Böhmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol 2000; 11: 71-79
5. Wolzt M, Schmetterer L, Ferber W et al. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. Am J Physiol 1997; 272: F178-F182
6. Jacobi J, Schneider MP, John S, Schmieder RE. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens 2002; 20: 525-530
7. Bech JN, Nielsen CB, Ivarsen P, Jensen KT, Pedersen EB. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans. Am J Physiol 1998; 274: F914-F923
8. Bech JN, Svedsen KB, Nielsen CB, Pedersen BP. The systemic renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans. Nephrol Dial Transplant 1999; 14: 641-647
9. Montanari A, Tateo E, Fasoli E et al. Angiotensin II blockade does not prevent renal effects of L-NAME in sodium-repleted humans. Hypertension 1997; 30: 557-562
10. Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002; 61: 1462-1468
11. Haynes WG, Hand MF, Dockrell ME et al. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol 1997; 272: F364-F371
12. Kielstein JT, Bode-Böger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895
13. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-36
14. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91: 2012-2019
15. Schmieder RE, Veelken R, Schobel HP, Dominiak P, Mann JF, Luft FC. Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol 1997; 8: 893-900
16. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16: 1030-1035
17. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15: 3-9
18. Wierema TK, Houben AJ, Kroon AA et al. Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. J Am Soc Nephrol 2001; 12: 1836-1843
19. Viberti GC, Wheeldon NM, for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678
20. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
21. Nijveldt RJ, Teerlink T, van der Hoven B et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30